Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Progressing After Prior Treatment

NCT07871110 is registered in ClinicalTrials.gov with TransThera Sciences (Nanjing), Inc. as lead sponsor.

NCT NCT07871110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07871110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Progressing After Prior Treatment
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
September 18, 2026
Completion date
June 30, 2029
Enrollment
182 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer (crpc)